UK and US customers set to benefit from Wasdell Group acquisition
Increased manufacturing and packaging capacity and service in the UK allows company to better service growing client base in the US who require a fully outsourced supply chain for their products within Europe.
The Wasdell Group has acquired Honeywood Limited, a specialist manufacturer and packager located in Northampton (UK).
The acquisition will strengthen and expand Wasdell’s manufacturing and packaging capacity in the UK to support the company’s growing client portfolio.
Commenting on the announcement, Vincent Dunne, CEO of The Wasdell Group said: “We are excited to announce the acquisition of Honeywood into the Wasdell Group. Expanding our current offering is the latest step in our ongoing strategic growth plans to meet rising demand for outsourced pharmaceutical services.
“By increasing our capacity and service offerings here in the UK, we will be able better service our growing client base in the US as they look to Wasdell to provide a fully outsourced supply chain for their products within Europe.”
Bringing additional experience into the Wasdell Group, Honeywood has operated as a contract manufacturer to the pharmaceutical and healthcare industries for over 20 years.
Martin Tedham, Chairman of the Wasdell Group added: “Honeywood caught our attention due to its synergies with the existing Wasdell operations. In particular, its oral liquid manufacturing capabilities will allow us to instantly increase capacity beyond our Newcastle upon Tyne facilty to meet customer requests.
“Customers will benefit from expanded services, capacity and continuity. Honeywood’s operations will easily integrate into our current operations, and we are looking forward to collaborating with the current owners and staff moving forward.”
The acquired site will also help to maintain the group’s additional portfolio of nutraceutical clients.
This news follows the recent announcement of the group’s European headquarters in Dundalk, Ireland, a custom-built state-of-the-art facility that is set to open its doors later this month.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance